| Metric | Value (₹ Cr) | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue | 3.1K | 19.4% | 61.8% |
| Total Income | 3.1K | 19.3% | 60.9% |
| Expenditure | 2.5K | 20.1% | 45.0% |
| PBT | 542.70 | 16.1% | 232.9% |
| Net Profit | 397.68 | 15.3% | 234.9% |
| OPM | 20.38% | 0.58pp | 9.64pp |
| NPM | 12.86% | 0.45pp | 6.68pp |
| EPS | 29.16 | 15.3% | 234.8% |
Record PAT Masks the Real Story: AI Segment in Retreat
Deepak Nitrite posted record ₹398 Cr PAT (+235% YoY), but 80% of consolidated EBIT came from phenolics at cycle peak. The Advanced Intermediates segment—the growth engine—saw EBIT fall 27% quarter-on-quarter; new asset ramps are absorbing slower than guided. Polycarbonate entry pushed to FY31; the stock is down 52% from its all-time high.
₹398 Cr
+235% YoY
₹515 Cr
22% margin, +23% QoQ
₹49 Cr
6% margin, -27% QoQ
The quarter in one sentence
Deepak Nitrite delivered record quarterly profit, but 80% of consolidated EBIT came from phenolics at commodity cycle peak. The Advanced Intermediates segment—the company's platform for long-term value creation—saw profitability collapse 27% quarter-on-quarter, signalling that new asset ramps are running slower than guided. The stock, down 52% from its all-time high, is pricing in skepticism that management can execute the recovery.
Where the profit came from
Phenolics drove Q2, posting ₹2,291 Cr revenue (highest ever, +72% YoY) and ₹515 Cr EBIT (22% margin). This segment is riding three tailwinds: a globally tight propylene market (pushing import costs higher, favoring Indian producers), domestic demand resilience (laminates, chemicals, autos stable at 6–7% annual growth), and Deepak's 4 lakh tonne capacity sustained on a debottlenecked basis. But management is candid: 'not a super cycle'—the market is at peak, driven by geopolitical supply disruptions, not structural demand.
Here is the tension. Advanced Intermediates, the growth segment Deepak is building via MIBK, MIBC, acetophenone, nitration, fluorination, and hydrogenation plants, posted only ₹49 Cr EBIT in Q2 (6% margin)—down 27% from Q1's ₹67 Cr. Revenue rose 38% YoY but stayed flat quarter-on-quarter at ₹811 Cr, entirely masked by phenolics dominance in the headline. These new assets, commissioned on schedule, are running at 60% utilization (MIBK/MIBC) and just launched (acetophenone ramping Q3). Market absorption is slower than historical cycles would suggest. This is not a supply problem; it is a demand-ramp issue.
Achieved highest ever quarterly revenue and EBITDA
Q2 revenue ₹3,091 Cr (best-ever Q2), consolidated EBITDA ₹643 Cr (+187% YoY)
Supported
Phenolics highest ever quarterly revenue
Phenol segment ₹2,291 Cr (+72% YoY, +29% QoQ), confirmed as record
Supported
MIBK/MIBC/acetophenone operational by Q2
Both commissioned Q2; MIBK/MIBC at 60% utilization, acetophenone ramping Q3 onwards
Supported, but underutilized
H2 FY27 AI margin recovery expected toward Q1 levels (11%)
Management guided Q3 EBIT % 'between Q1 and Q2, closer to Q1'
Supported (guidance maintained)
What changed on this call
Three strategic shifts from the Q1 FY27 call:
Polycarbonate entry pushed from FY28–29 to FY31—a 2-year delay. Management now frames this as a pilot (running in Germany) moving to commercial scale in FY31, with interim resin imports bridging the gap.
Capex profile re-phased: less in FY27 (₹800–900 Cr H2 vs ₹3.2 Cr initially guided), more in FY28–30. Total ₹11.7 Cr remains unchanged; just deferred. Equity funding ~done; debt is the main lever.
Phenol cycle reassessment: no longer 'structural growth' but explicitly 'at peak' driven by geopolitical supply disruptions and freight tightness. If normalized, margin compression of 5–10 percentage points probable.
AI margin recovery timeline extended: new assets phased ramp over FY27–28 (not immediate). Target remains 14–15% EBIT margin by FY28–29, but absolute EBIT ₹240–400 Cr is contingent on 100%+ utilization (currently 60%).
The bull-bear ledger
Record Q2 delivery on phenolics (₹2,291 Cr revenue, 22% EBIT margin) backed by structural domestic demand (laminates, chemicals, autos growing 6–7% annually)
New asset suite (chlorination, nitration, fluorination, hydrogenation) operational; REACH registration unlocks EU export for MIBK/MIBC
Polycarbonate platform (FY31 entry) de-risks commodity cyclicality; integrated phenol-to-polycarbonate supply is a structural moat
Net debt improved to ₹1,657 Cr (net D/E 0.25x); working capital cycle at 53 days showing operational discipline
Phenol cycle at peak; normalization of geopolitical disruptions will compress margins 5–10 percentage points. Propylene supply tightness constrains ramp above 4 lakh tonne
AI segment EBIT fell 27% QoQ despite revenue +38% YoY—profitability deteriorating, not ramping as guided. 60% utilization suggests slower market absorption
Polycarbonate timeline slipped FY29→FY31; 18-month execution window is aggressive. Design, permitting, and customer qualification delay risk material
Reported PAT growth is price-driven, not volume-driven (management: 'volume roughly flat YoY'). Organic growth dependent on commodity cycle, not structural expansion
Risks, ranked by how much they should concern a holder
Phenol cycle peak → margin compression
HighPhenol EBIT margin at 22% reflects geopolitical tailwinds (freight, import tightness, propylene supply disruptions). Management candid: 'not a super cycle.' Normalization will compress margins 5–10pp, cutting PAT ₹50–100 Cr+ per percentage point. Propylene feedstock tightness also constrains ramp above 4 lakh tonne.
AI margin recovery timing uncertain
HighQ2 AI EBIT fell 27% QoQ; target 14–15% margin not imminent. Management guided Q3 'closer to Q1' (11%), but new assets running at 60% utilization. If market absorption slower than expected, recovery could slip into FY28 or beyond, compressing ROE on ₹700 Cr+ H1 capex.
Polycarbonate execution risk & 2-year delay
HighFY31 entry is 18 months away; requires PDH plant ramp, resin pilot qualification at scale, and customer approvals across 500+ grades. Any slip extends timeline further. At ₹3,000+ Cr capex (60% of total program), delay directly impacts medium-term returns.
New asset underutilization
MediumMIBK/MIBC at 60%, acetophenone just ramping Q3. If market absorption slower, utilization stuck at 70–80% through FY28, leaving 20–30% capex unproductive. CDMO and specialty molecules still early-stage (kilo-lab to pilot phase).
Macro / geopolitical volatility reversal
MediumSupply-chain normalization, freight normalization, or increased propylene / ammonia exports could reverse tailwinds. Phenol spreads would compress; AI raw material costs might fall, creating a double margin squeeze. Domestic demand resilient but not immune to global moderation.
How the market is reading this
The stock reacted day-1 +2.91% (delivery 39.1%), holding gains into day-3 (+2.99%). The initial pop suggests the market validated the reported profit and phenol strength. But this is deceiving: the stock is trading at ₹1,520.6, down 52% from its all-time high of ₹3,169 and below all key moving averages (SMA20 ₹1,540, SMA50 ₹1,603, SMA200 ₹1,620). RSI is 46.4 (neutral), not oversold. This disconnect—record profit but stock at a 52% drawdown—signals the market is skeptical that phenol cycle peak and AI margin deterioration will reverse.
Ownership flows are flat. FII holding steady at 6.25% (vs 6.19% prior quarter, +6bp); DII +29bp to 23.76%; promoter stable at 49.34%. No material institutional accumulation or trimming. The narrative: wait for AI margin recovery proof before re-rating.
The debate
What to watch next
1 · Q3 FY27 AI EBIT margin recovery
Management guided 'closer to Q1' (~11% from Q2's 6%). If Q3 comes in at 8–9%, recovery is phased and credibility on 14–15% FY28–29 target weakens. If 11%+, new asset ramp validates and re-rating risk emerges.
2 · MIBK/MIBC utilization trajectory
Currently 60%, targeting 100%+ by FY28. Track Q3 output and sales mix. If stuck at 70–80% by year-end, market absorption is slower than expected; risk to H2 FY27 guidance and FY28 EBIT accretion.
3 · Polycarbonate FY31 entry—permit & pilot progress
PDH plant (feedstock) and resin pilot qualification are gating items. Any permitting slip or pilot delay signals execution risk. Track investor presentation updates and management commentary on customer trial progress.
The number to track
AI EBIT in absolute terms (₹ Cr, not margin %). Q1 was ₹67 Cr, Q2 fell to ₹49 Cr. Q3 guidance path is 'between Q1 and Q2, closer to Q1' (so ₹55–62 Cr range). If Q3 delivers ₹60+ Cr, the recovery is credible. If ₹45–50 Cr, the ramp is stuck. That ₹15–20 Cr swing is the difference between a +15% 18-month EPS upside case and a −10% downside case. This number will determine whether polycarbonate thesis remains intact or needs recalibration.
Deepak Nitrite Q2 was a study in optics vs. substance. The headline—record ₹398 Cr PAT—is real, but it is a phenol story at commodity cycle peak. The future (polycarbonate, integrated platform, 14–15% AI EBIT) is credible long-term but not imminent. Management has earned credibility on execution (MIBK/MIBC on-time, propylene sourcing proactive, capex discipline), but the stock's 52% drawdown reflects justified caution on timing and AI ramp credibility. Wait for Q3 AI recovery proof before stepping in; if it lands, the narrative resets to 'platform transition validated' and re-rating risk emerges.
Deepak Nitrite's Earnings Challenge: Can Growth Sustain After Record Q1?
Q1 FY27 delivered a stunning 207% profit surge and double-digit volume growth. Q2 faces the barre test: whether the margin expansion from fresh MIBK/MIBC capacity and phenol momentum can hold amid normal seasonal softness, or mark a one-off peak.
What to Expect: Sustenance Over Records
Q1 FY27 was exceptional: consolidated revenue ₹2,577.6 Cr (+36% YoY), operating EBITDA ₹540.2 Cr (+185%), PAT ₹345 Cr (+207%), with EBITDA margin doubling to 20.96%. Both Phenolics and Advanced Intermediates hummed. Q2 enters a different context: April–June summer typically moderates specialty-chemical demand and export realizations, fresh capex ramps volume but not always at peak utilization or spread. Expect revenue to moderate sequentially to the ₹2,200–2,400 Cr range, with EBITDA margins normalizing to 17–19%—still robust, but 200bp down from Q1's extraordinary print.
~₹2,200–2,400 Cr
Sequential normalization from Q1's ₹2,577.6; YoY growth likely still double-digit
~17–19%
Down from Q1's 20.96%; reflects seasonal demand and production ramp leverage
~₹150–200 Cr
Normalized from Q1's exceptional ₹345 Cr; YoY growth trajectory to watch
Ramp phase
MIBK/MIBC (₹735 Cr plant) and Chlor plant (₹300 Cr) just commissioned; expect modest Q2 build
A strong quarter would deliver ₹2,400+ Cr revenue with EBITDA margins holding at or above 18%, signaling that phenol and intermediate demand remain firm and capex ramps hold their utilization edge. A weak print would see revenue slip below ₹2,200 Cr or margins compress below 16%, indicating that the bounce was concentrated in a single spike or that oversupply / export pressure has returned sooner than expected.
On Track? The Capex Execution Playbook
Deepak Nitrite has signaled FY27 margins will surpass FY26, driven by capacity ramps and product mix. The evidence is credible: in August–September, it commissioned a ₹735 Cr MIBK/MIBC facility, a ₹300 Cr chlorination plant, and cleared a ₹2,500 Cr BPA investment. This capex cadence—moving from approval to commercial operation inside 12 months—demonstrates execution rigor. Q2 is still in the ramp phase; don't expect full-plant margin contribution yet. But if volumes and spreads hold, the full-year guide (margins up YoY) becomes credible. Watch for evidence on the earnings call: utilization rates on new plants, customer offtake, any pricing pressure.
What the Street Says
Since Last Quarter: Capex Milestones and Guidance Anchors
1 · Capex Commissioning (Aug–Sep 2026)
MIBK/MIBC plant (₹735 Cr) and Chlorination plant (₹300 Cr) both now operational. Subsidiary DCTL invested ₹80 Cr in new OCRPS to fund ops. Volume ramp expected Q2–Q3; margin contribution marginal until utilization > 50%.
2 · BPA Investment Approved (Aug 2026)
DCTL Board cleared ₹2,500 Cr capex for 240 KTA Bisphenol A facility. This is a 3–4 year build (est. FY28–FY29 commercial), not material to Q2 or FY27 earnings but signals long-term growth playbook.
3 · Subsidiary Debt Guarantee (Jul 2026)
Deepak Nitrite guaranteed a $78.43M term loan for subsidiary DOIL (Oman Ops). Routine capex financing; no operational impact on Q2.
4 · Management Change (Aug 2026)
SBU Head of Life Sciences resigned; board composition updated. Minor change; no material operational signal.
5 · Trading Window Closure (Sep 2026)
Standard insider trading blackout for results publication. No unusual director buying/selling pre-announcement.
The Setup
Deepak Nitrite's Q2 FY27 story hinges on two moves: (1) whether the 207% profit surge in Q1 was a sustainable step-up or a seasonal spike, and (2) whether fresh capex (MIBK/MIBC, Chlorination) can reach 60%+ utilization and maintain margin profile into Q3–Q4. The Street is cautiously optimistic (Hold, 24% upside), but execution on volume ramp and spot spreads will define the narrative. Valuation at 25–26x FY27E EPS leaves no room for miss.
Three Things to Watch on Result Day (Oct 30)
1 · EBITDA Margin Trajectory
If Q2 EBITDA margin ≥ 18%, it signals Q1 was not a peak but a new run-rate level. Below 16% would suggest mean reversion. Listen to mgmt commentary on pricing pressure (export realizations, domestic competition) and utilization.
2 · Capex Utilization Update
CFO should quantify production from the MIBK/MIBC and Chlorination plants: volume shipped, realized pricing vs guidance, path to 75%+ utilization. This is the execution metric investors care about most.
3 · FY27 Guidance Reiteration
Will mgmt reaffirm that FY27 margins will exceed FY26? If guidance is raised or lowered in light of Q2 print, it resets Street expectations. Watch for any commentary on FY28 (BPA plant impact timeline, polycarbonate facility progress).
Deepak Nitrite reports Q2 FY27 results on October 29, 2026 (Board meeting), with a management earnings call on October 30 at 3:30 PM IST. The stock trades at ₹1,487.4, down 53% from its ATH but up 16% from its 52-week low. Street consensus is Hold with a ₹1,852 target, premised on sustained margin expansion from capex ramps. Q2 is the test: can it deliver 17%+ EBITDA margin and show credible volume ramp in new plants? Or does it normalize back toward 14–15%, signaling that Q1 was a seasonal spike? The answer will anchor Street expectations through H2 FY27.
Record PAT masks AI margin compression; polycarbonate platform de-risks cycles
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Buy
confidence 7/10
Grade B
Hit Q2 delivery on phenol; AI margin compression expected as new assets ramp—phasing in line with guidance
Optimistic
next 1–2 quarters
Very Optimistic
multi-year
Record Q2 delivery (PAT +235% YoY, ₹3,091 Cr revenue) backed by phenol strength and new asset ramps; long-term polycarbonate platform + integrated value chains de-risk commodity cyclicality. Key risk: phenol cycle at peak, AI margin recovery timing uncertain, propylene supply constraints.
₹3091 Cr
Revenue · +61.8% YoY₹398 Cr
Reported PAT · +234.9% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Achieved highest ever quarterly revenue and EBITDA
METQ2 revenue ₹3,091 Cr (best-ever Q2), consolidated EBITDA ₹643 Cr (+187% YoY)
Phenolics highest ever quarterly revenue
METPhenol segment ₹2,291 Cr (+72% YoY, +29% QoQ), confirmed as record
Advanced Intermediates buoyant Q1 demand, margins moderate in Q2
MISSQ2 revenue ₹811 Cr (flat QoQ), EBIT ₹49 Cr (down 27% QoQ from ₹67 Cr), margin 6%
Phenol 4 lakh tonne capacity sustained
METManagement: 'come close enough to 4 lakh tonnes plus or minus', constrained by propylene supply
MIBK/MIBC operational by Q2, acetophenone commissioned
METBoth commissioned Q2; MIBK/MIBC at 60% utilization, acetophenone ramp Q3 onwards
H2 FY27 AI margin recovery expected toward Q1 levels
METManagement guided Q3 EBIT % 'between Q1 and Q2, closer to Q1' (Q1: 11%, Q2: 6%)
Earnings quality
What changed since the last call
Phenol demand surge extends, now at "peak", not structural growth
NeutralQ1 call: strong domestic demand. Q2 call: 'geopolitical disruptions + supply tightness favorable, but not a super cycle.' Management reset expectations—peak cycle, not new normal.
Advanced Intermediates margin compression vs Q1 guidance
DowngradeQ1 implied recovery to 11%+ EBIT margin in Q2; instead Q2 delivered 6% margin. Root: 'lower capacity utilization' due to raw material cost volatility and demand moderation.
Polycarbonate timeline shifted from FY29 to FY30-31
DowngradeInvestor deck implied H2 FY28-29 polycarbonate entry; call confirms FY31 integration. Phenol/BPA commissioning in line, but polycarbonate resin plant delayed.
Capex profile: less FY27, more FY28-30
NeutralPrior: ₹3.2 Cr FY27 (of ₹11.5 Cr total). Now: ~₹800-900 Cr H2 FY27, ₹2.2-2.4 Cr FY28, ₹2.5 Cr FY28-29. Total ₹11.7 Cr (flat), just re-phased.
MIBK/MIBC launched on-schedule, but ramp slower than hoped
NewCommissioned Q2 as promised, but at 60% utilization targeting 100%. Indicates market absorption or internal yield challenges in early run.
The Q&A
Analysts pressed on AI margin recovery timing, phenol cycle sustainability, and polycarbonate approvals. Management held firm on 14-15% AI EBIT target (steady-state, not imminent), acknowledged phenol cycle peak candidly, and confirmed FY31 polycarbonate. Q&A was detailed but revealed no major concessions.
AI capacity utilization — Nirav Jimudia, Anvil Wealth
AnsweredQ3 EBIT margin expected between Q1 and Q2 levels, closer to Q1 (~11%). New assets ramping gradually; full utilization realization by FY28-29.
Phenol competition dynamics — Archit Joshi, Nuvama
AnsweredIndia's 2 lakh tonne new capacity growth already absorbed. China participates selectively (when imports cheaper). Deepak's debottlenecking + scale moat insulate us. Pricing power holds.
Advanced Intermediates EBIT guidance — Sanjesh Jain, ICICI
Answered₹240-400 crore in absolute terms at steady-state with 14-15% EBIT margin. New assets contribute ₹250+ Cr incremental EBIT as utilization improves.
Phenol demand and imports — Arun Prasath, Avendus
AnsweredIndia's consumption growing 6-7% annually; demand resilient for chemicals, laminates, autos. China not participating selectively. India's SKU diversity (specialty-grade) commands premium. Wallet share expansion, not commodity dumping.
Polycarbonate approval timeline — Ankur Periwal, Axis
AnsweredApprovals are for compounds, not resins. Resins being imported for now. FY31 integrated plant ramp-up; FY32+ selling compounds to the market alongside resin supply.
Capex guidance multi-year — Abhijit Akella, Kotak
Answered₹2.2-2.4 Cr FY28, ₹2.5 Cr FY28-29, ₹2.5-3 Cr balance FY29-30. Total ₹11.7 Cr. Equity mostly done (~₹50 Cr left), debt funding main lever.
Volume vs price growth mix — Adiya Iyer, HDFC
PartialVolume roughly flat YoY (Q1 shutdown impact). Growth is price realization + procurement efficiency. Optimal run rate achieved; headroom available but not maxed out.
Acetone captive consumption — Rohit Nagraj, 360 ONE
AnsweredIntegrated approach: 60-65% consumed captively, balance sold externally. Full utilization dependent on market demand; we optimize for profitability, not volume maximization.
New specialty molecules R&D — Rishabh Tripathi, Multi Dimensional
AnsweredCDMO opportunities being explored; R&D from kilo-lab to pilot scale in progress. Early-stage, not material revenue yet. Personal care and specialty laminates high-value focus areas.
China competitive pressure — Vansh Gupta, Prescient
AnsweredNo significant impact. Propylene/ammonia shortage benefits Indian makers. Integrated approach + multi-SKU moat shields us. India's growth story resilient; China not dominating here.
Guidance
No explicit FY27 revenue target; H1 ₹5,682 Cr suggests ₹11-12 Cr+ FY27
MediumPhenol sustains 4 LT; AI recovery in H2 FY27 drives incremental. Propylene supply constrains phenol upside.
Phenol: Sustain 20%+ EBIT margin; commodity cycle risk if feedstock inflation
HighQ2 demonstrated 22% phenol EBIT margin at peak cycle. Management realistic: 'not a super cycle,' but sustained at current levels likely H2 FY27.
AI EBIT margin: Recovery from 6% Q2 to 11% (Q1-like) in Q3; target 14-15% FY28-29
MediumDependent on new asset utilization ramp (nitration, etc.) and market absorption. Phased ramp expected; full steady-state ₹240-400 Cr absolute EBIT.
₹2.2-2.4 Cr FY28, ₹2.5 Cr FY28-29, ₹2.5-3 Cr FY29-30, total ₹11.7 Cr over 4 years
HighEquity funding ~done (₹50 Cr left); debt main lever (60:40 debt:equity agreed). Polycarbonate ~60% of capex; rest AI expansion & debottlenecking.
Risks the call surfaced
Phenol cycle peak
HighPhenol at 'peak' driven by geopolitical supply disruptions + freight tightness. Management explicit: 'not a super cycle.' Normalization risks 5-10% margin compression.
AI segment margin recovery timing
HighAI EBIT fell 27% QoQ despite revenue +38% YoY, margin only 6% vs target 14-15%. Recovery dependent on new asset full-load utilization (nitration, etc.) and market absorption. Phased ramp could extend recovery past FY28.
Polycarbonate execution & approval cycle
HighFY31 polycarbonate plant entry is 18 months away; requires feedstock PDH plant commissioning, resin pilot qualification at scale, and customer approvals across 500+ grades. Delay or cost overrun likely given specialty complexity.
Propylene feedstock supply
MediumPhenol ramp constrained by propylene availability; management notes 'disturbance with regards to propylene availability' in recent months. Non-traditional sourcing required at higher cost; limits margin expansion.
New asset underutilization
MediumMIBK/MIBC running at 60% utilization (vs target 100%+); acetophenone just launched (Q3 ramp uncertain). If market absorption slower than guided, AI margin recovery delayed; capex returns compressed.
Macro / geopolitical volatility
MediumStrong Q2 driven by supply-chain disruptions (freight, import tightness, China anti-involution). If geopolitical normalizes (freight costs fall, imports resume), tailwind reverses. Phenol cycle compressed; AI margin pressure.
Management
Score 8/10. Structured, quantified, candid on cycles (phenol peak acknowledgment) and execution risks (propylene supply, polycarbonate delay). NDA shields held where needed (customer names), but specifics on EBIT targets and capex provided. Hit Q2 delivery on phenolics (record revenue/EBIT); AI margin compression expected but timeline slippage on polycarbonate (FY29→FY30-31). Capex on track; equity funding mostly done.
1 · Q3 FY27
AI EBIT margin recovery toward 11% (Q1 level); acetophenone ramp-up
2 · H2 FY27
Phenol 4 LT sustained amid propylene supply tightness; MIBK/MIBC move toward 100% utilization
3 · H2 FY27
REACH registration approval for MIBK/MIBC opens EU export markets
Key risk: phenol cycle at peak, AI margin recovery timing uncertain, propylene supply constraints.